Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases

Journal of the Royal Society Interface

Volumn 10, Issue 79, 2013, Pages

  Shakya, Akhilesh Kumar ^a   Nandakumar, Kutty Selva ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adjuvant; Animal model; Autoimmunity; Polymer; Vaccine

Indexed keywords

ANTIGENS; BIOCOMPATIBILITY; BIODEGRADATION; BLOCK COPOLYMERS; IMMUNOLOGY; POLYMERS; VACCINES;

ADJUVANT; ANIMAL MODEL; AUTOIMMUNITY; CO-STIMULATORY SIGNAL; DEGREE OF BRANCHING; EXTERNAL STIMULUS; IMMUNE ACTIVATION; IMMUNE RESPONSE; INFECTIOUS DISEASE; INNATE IMMUNE SYSTEMS; LONG DURATION; NATURAL POLYSACCHARIDE; NONIONIC; POLYANHYDRIDES; POLYMERIC BACKBONE; SLOW RELEASE; SYNTHETIC POLYMERS; TOLL-LIKE RECEPTORS; UNDERLYING PRINCIPLES; UNDESIRABLE EFFECTS;

BIODEGRADABLE POLYMERS;

BETA GLUCAN; CHITOSAN; COPOLYMER; DENDRITIC CELL VACCINE; DIETHYLAMINOETHYLDEXTRAN; ETHYLAMINE; FREUND ADJUVANT; INFLAMMASOME; INULIN; LENTINAN; LIPOPOLYSACCHARIDE; MANNAN; MONTANIDE ISA 51; NEWCASTLE DISEASE VACCINE; POLY(N ISOPROPYLACRYLAMIDE); POLYACRYLIC ACID; POLYANHYDRIDE; POLYCAPROLACTONE; POLYELECTROLYTE; POLYGLACTIN; POLYGLUTAMIC ACID; POLYMER; POLYMETHACRYLIC ACID; POLYPHOSPHATE; POLYSACCHARIDE; POVIDONE; TOLL LIKE RECEPTOR; UNINDEXED DRUG; VACCINE; ZYMOSAN; IMMUNOLOGICAL ADJUVANT;

ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOCOMPATIBILITY; BIODEGRADABILITY; CANDIDA ALBICANS; EMULSION; GENE TARGETING; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLUENZA; INNATE IMMUNITY; JAPANESE ENCEPHALITIS; MELANOMA B16; MOLECULAR WEIGHT; MYASTHENIA GRAVIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; VACCINATION; VIRUS INFECTION; BIOLOGICAL MODEL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DESIGN; IMMUNOLOGY; INFECTION CONTROL; METHODOLOGY;

ANIMALIA;

ADJUVANTS, IMMUNOLOGIC; AUTOIMMUNITY; COMMUNICABLE DISEASE CONTROL; DELAYED-ACTION PREPARATIONS; DRUG DESIGN; HUMANS; MODELS, IMMUNOLOGICAL; POLYMERS; VACCINES;

EID: 84872228741     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2012.0536     Document Type: Review

References (161)

1. Bomford R. 1998 Will adjuvants be needed for vaccines of the future. In Modulation of the immune response to vaccine antigens Dev Biol Stand, vol. 92 (eds F Brown, LR Haaheim), pp. 13-18. Basel, Switzerland: Karger.
2. Vogel FR. 1998 Adjuvants in perspective. In Modulation of the immune response to vaccine antigens Dev Biol Stand, vol. 92 (eds F Brown, LR Haaheim), pp. 241-248. Basel, Switzerland: Karger.
3. Nandakumar KS, Holmdahl R. 2006 Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res. Ther. 8, 223. (doi:10.1186/ar2089)
4. Lindblad EB. 1995 Aluminium adjuvants. In The theory and practical application of adjuvants (ed. DES Stewart-Tull), pp. 21-35. Chichester, UK: John Wiley & Sons Ltd.
5. Johnson HE, DeAvila DM, Chang F, Reeves JJ. 1988 Active immunization of heifers against luteinizing hormone-releasing hormone, human chorionic gonadotropin and bovine luteinizing hormone. J. Anim. Sci. 66, 719-726.
6. Jacobs DM. 1979 Synergy between T cell-replacing factor and bacterial lipopolysaccharide (LPS) in the primary antibody response in vitro: a model for lipopolysaccharide adjuvant action. J. Immunol. 122, 1421-1426. (Pubitemid 9178776)
7. Heufler C, Koch F, Schuler G. 1988 Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 167, 700-705. (doi:10.1084/jem.167.2.700)
8. Segal BM, Chang JT, Shevach EM. 2000 CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. 164, 5683-5688. (Pubitemid 30389809)
9. Freund J. 1956 The mode of action of immunologic adjuvants. Adv. Tuberc. Res. 7, 130-148.
10. Matthys P, Vermeire K, Billiau A. 2001 Mac-1+ myelopoiesis induced by complete Freund's adjuvant (CFA): a clue to the paradoxical effects of IFN-γ in autoimmune disease models. Trends Immunol. 22, 367-371. (doi:10.1016/S1471-4906(01)01937-8)
11. Heeger PS, Forsthuber T, Shive C, Biekert E, Genain C, Hofstetter HH, Karulin A, Lehmann PV. 2000 Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J. Immunol. 164, 5771-5781. (Pubitemid 30389820)
12. Stills HF, Bailey MQ. 1991 The use of Freund's complete adjuvant. Lab. Anim. 20, 25-30.
13. Bauer C et al. 2010 Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59, 1192-1199. (doi:10.1136/gut.2009.197822)
14. Houston WE, Crabbs CL, Kremer RJ, Springer JW. 1976 Adjuvant effects of diethylaminoethyl-dextran. Infect. Immun. 13, 1559-1562.
15. Bachelder EM, Beaudette TT, Broaders KE, Frechet JMJ, Albrecht MT, Mateczun AJ, Ainslie KM, Pesce JT, Keane-Myers AM. 2010 In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol. Pharm. 7, 826-835. (doi:10.1021/mp900311x)
16. Drandarska I, Kussovski V, Nikolaeva S, Markova N. 2005 Combined immunomodulating effects of BCG and Lentinan after intranasal application in guinea pigs. Int. Immunopharmacol. 5, 795-803. (doi:10.1016/j.intimp.2004.12. 008)
17. Guo Z, Hu Y, Wang D, Ma X, Zhao X, Zhao B, Wang J, Liu P. 2009 Sulfated modification can enhance the adjuvanticity of lentinan and improve the immune effect of ND vaccine. Vaccine 27, 660-665. (doi:10.1016/j.vaccine.2008.11.038)
18. Cooper PD, Steele EJ. 1988 The adjuvanticity of γ inulin. Immunol. Cell Biol. 66, 345-352. (doi:10.1038/icb.1988.45)
19. Cristillo AD et al. 2011 Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J. Gen. Virol. 92, 128-140. (doi:10.1099/vir.0.023242-0)
20. Stambas J, Pietersz G, McKenzie IF, Cheers C. 2002 Oxidised mannan as a novel adjuvant inducing mucosal IgA production. Vaccine 20, 1068-1078. (doi:10.1016/S0264-410X(01)00456-X)
21. Lee JK, Lee MK, Yun YP, Kim Y, Kim JS, Kim YS, Kim K, Han SS, Lee CK. 2001 Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells. Int. Immunopharmacol. 1, 1275-1284. (doi:10.1016/S1567-5769(01)00052-2)
22. Prego C, Paolicelli P, Díaz B, Vicente S, Sánchez A, González-Fernández A, Alonso MJ. 2010 Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine 28, 2607-2614. (doi:10.1016/j.vaccine.2010.01.011)
23. Ghendon Y et al. 2009 Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J. Med. Virol. 81, 494-506. (doi:10.1002/jmv.21415)
24. Kotze AF, Luessen HL, de Leeuw BJ, de Boer BG, Verhoef JC, Junginger HE. 1997 N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm. Res. 14, 1197-1202. (doi:10.1023/A:1012106907708)
25. Akagi T, Kaneko T, Kida T, Akashi M. 2005 Preparation and characterization of biodegradable nanoparticles based on poly(γ-glutamic acid) with L-phenylalanine as a protein carrier. J. Control. Release 108, 226-236. (doi:10.1016/j.jconrel.2005.08.003)
26. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. 2002 Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1, 111-118. (doi:10.1586/14760584.1.1.111)
27. Andrianov AK, Marin A, Chen J. 2006 Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy)phosphazene]. Biomacromolecules 7, 394-399. (doi:10.1021/bm050790a)
28. McNeal MM, Rae MN, Ward RL. 1999 Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17, 1573-1580. (doi:10.1016/S0264-410X(98)00359-4)
29. De-Geest BG et al. 2012 Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection. ACS Nano 6, 2136-2149. (doi:10.1021/nn205099c)
30. Chen CH et al. 2012 Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch. Int. J. Nanomed. 7, 607-621.
31. Conde BC, Schiltz E, Yu J, Minion FC, Phillips GJ, Wannemuehler MJ, Narasimhan B. 2010 Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestis antigens. Acta Biomater. 6, 3110-3119. (doi:10.1016/j.actbio.2010.01.040)
32. Yoncheva K, Lizarraga E, Irache JM. 2005 Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. Eur. J. Pharm. Sci. 24, 411-419. (doi:10.1016/j.ejps.2004.12.002)
33. Todd CW, Pozzi LAM, Guarnaccia JR, Balasubramanian M, Henkf WJ, Youngert LE, Newman MJ. 1997 Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations. Vaccine 15, 564-570. (doi:10.1016/S0264-410X(97)00209-0)
34. Christian NA et al. 2007 Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling. Bioconjug. Chem. 18, 31-40. (doi:10.1021/bc0601267)
35. Quer CB, Marsden HR, Romeijn S, Zope H, Kros A, Jiskoot W. 2011 Polymersomes enhance the immunogenicity of influenza subunit vaccine. Polym. Chem. 2, 1482-1485. (doi:10.1039/c1py00010a)
36. Kreuter J. 1992 Physicochemical characterization of nanoparticles and their potential for vaccine preparation. Vac. Res. 1, 93-98.
37. Lou PJ, Cheng WF, Chung YC, Cheng CY, Chiu LH, Young TH. 2009 PMMA particle-mediated DNA vaccine for cervical cancer. J. Biomed. Mater. Res. A 88, 849-857. (doi:10.1002/jbm.a.31919)
38. Saini V, Jain V, Sudheesh MS, Jaganathan KS, Murthy PK, Kohli DV. 2011 Comparison of humoral and cell mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen. Int. J. Pharm. 408, 50-57. (doi:10.1016/j.ijpharm.2011.01.045)
39. Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. 2012 Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS ONE 7, e31472. (doi:10.1371/journal.pone. 0031472)
40. Shi L, Caulfield MJ, Chern RT, Wilson RA, Sanyal G, Volkin DB. 2002 Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J. Pharm. Sci. 91, 1019-1035. (doi:10.1002/jps.10042)
41. He XW et al. 2005 Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg. J. Gen. Virol. 86, 601-610. (doi:10.1099/vir.0.80575-0)
42. Benoit MA, Baras B, Poulain-Godefroy O, Schacht AM, Capron A, Gillard J, Riveau G. 1998 Evaluation of the antibody response after oral immunization by microparticles containing as antigen from Schistosoma mansoni. In Biomedical science and technology recent developments in the pharmaceutical and medical sciences (eds A Hincal, H Kas), pp. 137-144. New York, NY: Plenum.
43. Murillo M, Goni MM, Irache JM, Arangoa MA, Blasco JM, Gamazo C. 2002 Modulation of the cellular immune response after oral or subcutaneous immunization with microparticles containing Brucella ovis antigens. J. Control. Release 85, 237-246. (doi:10.1016/S0168-3659(02)00276-6)
44. Madan T, Munshi N, De TK, Maitra A, Sarma PU, Aggarwal SS. 1997 Biodegradable nanoparticles as a sustained release system for the antigens/allergens of Aspergillus fumigatus : preparation and characterisation. Int. J. Pharm. 159, 135-147. (doi:10.1016/S0378-5173(97)00278-0)
45. Mastrobattista E, Hennink WE. 2012 Polymers for gene delivery charged for success. Nat. Mater. 11, 10-12. (doi:10.1038/nmat3209)
46. Kaistha J, Sockey J, Singh S, Kumar S, John PC, Sharma NC. 1996 Adjuvant effect of DEAE-dextran and tetanus toxoid on whole cell heat inactivated phenol preserved typhoid vaccine. Indian J. Pathol. Immunol. 39, 287-292.
47. Irinoda K, Masihi KN, Chihara G, Kaneko Y, Katori T. 1992 Stimulation of microbicidal host defence mechanisms against aerosol influenza virus infection by lentinan. Int. J. Immunopharmacol. 14, 971-977. (doi:10.1016/0192-0561(92) 90140-G)
48. Wang J, Zhou ZD, Xia DJ. 2007 Study on effect of lentinan in enhancing anti-tumor action of dendritic cytoma vaccine and its mechanism. Zhongguo Zhong Xi Yi Jie He Za Zhi 27, 60-64.
49. Bruley-Rosset M, Florentin I, Mathe G. 1976 In vivo and in vitro macrophage activation by systemic adjuvants. Agents Actions 6, 251-255. (doi:10.1007/BF01972217)
50. Cooper PD, Carter M. 1986 Anti-complementary action of polymorphic 'solubility forms' of particulate inulin. Mol. Immunol. 23, 895-901. (doi:10.1016/0161-5890(86)90075-1)
51. Cooper PD, Petrovsky N. 2011 δ inulin: a novel, immunologically-active, stable packing structure comprising β-D-[2 → 1] poly(fructo-furanosyl) α-D-glucose polymers. Glycobiology 21, 595-606. (doi:10.1093/glycob/cwq201)
52. Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, Toriniwa H, Petrovsky N. 2010 An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J. Gen. Virol. 91, 1407-1417. (doi:10.1099/vir.0.019190-0)
53. Petrovsky N, Cooper PD. 2011 Carbohydrate-based immune adjuvants. Expert Rev. Vaccines 10, 523-537. (doi:10.1586/erv.11.30)
54. Thiel S, Gadjeva M. 2009 Humoral pattern recognition molecules: mannan-binding lectin and ficolins. Adv. Exp. Med. Biol. 653, 58-73. (doi:10.1007/978-1-4419-0901-5-5)
55. Takahara K, Yashima Y, Omatsu Y, Yoshida H, Kimura Y, Kang YS, Steiman RM, Park CG, Inaba K. 2004 Functional comparison of the mouse DC-SIGN, SIGNR1, SIGNR3 and Langerin, C-type lectins. Int. Immunol. 16, 819-829. (doi:10.1093/intimm/dxh084)
56. Sheng KC, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, Apostolopoulos V. 2006 Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118, 372-383. (doi:10.1111/j.1365-2567.2006.02384.x)
57. McKenzie IF, Apostolopoulos V, Lees C, Xing PX, Lofthouse S, Osinski C, Popovski V, Acres B, Pietersz G. 1998 Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses. Vet. Immunol. Immunopathol. 63, 185-190. (doi:10.1016/S0165-2427(98)00094-4)
58. Yoshitomi H et al. 2005 A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J. Exp. Med. 201, 949-960. (doi:10.1084/jem.20041758)
59. Hashimoto M et al. 2010 Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. 207, 1135-1143. (doi:10.1084/jem. 20092301)
60. Arca HC, Gunbeyaz M, Senel S. 2009 Chitosan-based systems for the delivery of vaccine antigens. Expert Rev. Vaccines 8, 937-953. (doi:10.1586/erv.09.47)
61. Wen ZS, Xu YL, Zou XT, Xu ZR. 2011 Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar. Drugs 9, 1038-1055. (doi:10.3390/md9061038)
62. Zhao K, Shi X, Zhao Y, Wei H, Sun Q, Huang T, Zhang X, Wang Y. 2011 Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine 29, 8549-8556. (doi:10.1016/j.vaccine.2011.09.029)
63. Borges O, Cordeiro-da-Silva A, Tavares J, Santarém N, de Sousa A, Borchard G, Junginger HE. 2008 Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur. J. Pharm. 69, 405-416. (doi:10.1016/j.ejpb.2008.01.019)
64. Gong YF, Xie Y, Zhou NJ, Chen J, Zhou XJ, Lu NH, Wang CW. 2007 Cellular immunity induced by H. pylori vaccine with chitosan as adjuvant. Chin. J. Cell Mol. Immunol. 23, 595-599.
65. Sayin B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH. 2009 TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccine. Eur. J. Pharm. Sci. 38, 362-369. (doi:10.1016/j.ejps.2009. 08.010)
66. Verheul RJ, Slütter B, Bal SM, Bouwstra JA, Jiskoot W, Hennink WE. 2011 Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination. J. Control. Release 156, 46-52. (doi:10.1016/j.jconrel.2011.07.014)
67. Uto T, Akagi T, Yoshinaga K, Toyama M, Akashi M, Baba M. 2011 The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials 32, 5206-5212. (doi:10.1016/j.biomaterials.2011.03.052)
68. Kurosaki T, Kitahara T, Nakamura T, Nishida K, Fumoto S, Kodama Y, Nakagawa H, Higuchi N, Sasaki H. 2012 Development of effective cancer vaccine using targeting system of antigen protein to APCs. Pharm. Res. 29, 483-489. (doi:10.1007/s11095-011-0571-x)
69. Chang JCC, Diveley JP, Savary JR, Jensen FC. 1998 Adjuvant activity of incomplete Freund's adjuvant. Adv. Drug Deliv. Rev. 32, 173-186. (doi:10.1016/S0169-409X(98)00009-X)
70. Vogel FR, Powell MF. 1995 A compendium of vaccine adjuvants and excipients. In Vaccine design: the subunit and adjuvant approach (eds MF Powell, MJ Newman), pp. 141-228. New York, NY: Plenum.
71. Podda A. 2001 The adjuvanted influenza vaccines with novel adjuvants: experience with MF59-adjuvanted vaccine. Vaccine 19, 2673-2680. (doi:10.1016/S0264-410X(00)00499-0)
72. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-Roels G. 2007 Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370, 580-589. (doi:10.1016/S0140-6736(07) 61297-5)
73. Gaucher G, Poreba M, Ravenelle F, Leroux JC. 2007 Poly(N-vinyl- pyrrolidone)-block-poly(D,L-lactide) as polymeric emulsifier for the preparation of biodegradable nanoparticles. J. Pharm. Sci. 96, 1763-1775. (doi:10.1002/jps.20833)
74. Newman MJ, Balusubramanian M, Todd CW. 1998 Development of adjuvant-active nonionic block copolymers. Adv. Drug Deliv. Rev. 32, 199-223. (doi:10.1016/S0169-409X(98)00011-8)
75. Jeong B, Bae YH, Lee DS, Kim SW. 1997 Biodegradable block copolymers as injectable drug-delivery systems. Nature 388, 860-862. (doi:10.1038/42218)
76. Huang MH, Huang CY, Lien SP, Siao SY, Chou AH, Chen HW, Liu SJ, Leng CH, Chong P. 2009 Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant. Pharm. Res. 26, 1856-1862. (doi:10.1007/s11095-009- 9898-y)
77. Andrianov AK, Payne LG. 1998 Polymeric carriers for oral uptake of microparticulates. Adv. Drug Deliv. Rev. 34, 155-170. (doi:10.1016/S0169- 409X(98)00038-6)
78. Payne LG, Jenkis SA, Woods AL, Grund EM, Geribo WE, Loebelenz JR, Andrianov AK, Roberts BE. 1998 Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 17, 92-98. (doi:10.1016/S0264-410X(97)00149-7)
79. Mutwiri G, Benjamin P, Soita H, Townsend H, Yost R, Roberts B, Andrianov AK, Babiuk LA. 2007 Poly[di(sodium carboxylatoethylphenoxy) phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25, 1204-1213. (doi:10.1016/j.vaccine.2006.10. 011)
80. Mutwiri G, Benjamin P, Soita H, Babiuk LA. 2008 Co-administration of polyphosphazenes β with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with hepatitis B virus surface antigen. Vaccine 26, 2680-2688. (doi:10.1016/j.vaccine.2008.03.031)
81. Shim DH, Ko HJ, Volker G, Potter AA, Mutwiri G, Babiuk LA, Kweon MN. 2010 Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. Vaccine 28, 2311-2317. (doi:10.1016/j.vaccine.2009.12.069)
82. Andrianov AK, DeCollibus DP, Gillis HA, Kha HH, Marin A, Prausnitz MR, Babiuk LA, Townsend H, Mutwiri G. 2009 Poly[di(carboxylatophenoxy) phosphazene] is a potent adjuvant for intradermal immunization. Proc. Natl Acad. Sci. USA 106, 18 936-18 941. (doi:10.1073/pnas.0908842106)
83. De-Geest BG, Sanders NN, Sukhorukov GB, Demeester J, De-Smedt SC. 2007 Release mechanisms for polyelectrolyte capsules. Chem. Soc. Rev. 36, 636-649. (doi:10.1039/b600460c)
84. Sexton A, Whitney PG, Chong SF, Zelikin AN, Johnston APR, De-Rose R, Brooks AG, Caruso F, Kent SJ. 2009 A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano 3, 3391-3400. (doi:10.1021/nn900715g)
85. De-Koker S, Naessens T, De-Geest BG, Bogaert P, Demeester J, De-Smedt S, Grooten J. 2010 Biodegradable polyelectrolyte microcapsules: antigen delivery tools with Th17 skewing activity after pulmonary delivery. J. Immunol. 184, 203-211. (doi:10.4049/jimmunol.0803591)
86. Yu AM, Wang YJ, Barlow E, Caruso F. 2005 Mesoporous silica particles as templates for preparing enzyme-loaded biocompatible microcapsules. Adv. Mater. 17, 1737-1741. (doi:10.1002/adma.200402045)
87. Decher G. 1997 Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 277, 1232-1237. (doi:10.1126/science.277.5330.1232)
88. Khaitov RM. 1990 Molecular bases for the construction of artificial immunogens. J. Biomed. Sci. 1, 122-126.
89. Nandakumar KS, Muthukkaruppan VR. 1999 Influence of immunopotentiators on the antiporin immunoglobulin G subclass: distribution and protective immunity against murine salmonellosis. Scand. J. Immunol. 50, 188-194. (doi:10.1046/j.1365-3083.1999.00576.x)
90. Petrov RV, Khaitov RM, Ataullakhanov RI. 1987 Artificial antigens and vaccines based on non-natural polyelectrolytes. Sov. Med. Rev. D Immunol. Rev. 1, 241-443.
91. Mallapragada SK, Narasimhan B. 2008 Immunomodulatory biomaterials. Int. J. Pharm. 364, 265-271. (doi:10.1016/j.ijpharm.2008.06.030)
92. Torres MP, Determan AS, Anderson GL, Mallapragada SK, Narasimhan B. 2007 Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials 28, 108-116. (doi:10.1016/j.biomaterials.2006.08.047)
93. Adler AF, Petersen LK, Wilson JH, Torres MP, Thorstenson JB, Gardner SW, Mallapragada SK, Wannemuehler MJ, Narasimhan B. 2009 High throughput cell-based screening of biodegradable polyanhydride libraries. Comb. Chem. High Throughput Screen 12, 634-645. (doi:10.2174/138620709788923764)
94. Shen EE, Kipper MJ, Dziadul B, Lim MK, Narasimhan B. 2002 Mechanistic relationships between polymer microstructure and release kinetics in bioerodible polyanhydrides. J. Control. Release 82, 115-125. (doi:10.1016/S0168-3659(02) 00125-6)
95. Kipper MJ, Wilson JH, Wannemuehler MJ, Narasimhan B. 2006 Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. J. Biomed. Mater. Res. A 76, 798-810. (doi:10.1002/jbm.a. 30545)
96. Torres MP, Wilson-Welder JH, Lopac SK, Phanse Y, Carrillo-Conde B, Ramer-Tait AE, Bellaire BH, Wannemuehler MJ, Narasimhan B. 2011 Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater. 7, 2857-2864. (doi:10.1016/j.actbio.2011.03.023)
97. Petersen LK, Ramer-Tait AE, Broderick SR, Kong CS, Ulery BD, Rajan K, Wannemuehler MJ, Narasimhan B. 2011 Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Biomaterials 32, 6815-6822. (doi:10.1016/j.biomaterials.2011.05.063)
98. Camacho AI, Costa Martins RD, Tamayo I, de-Souza J, Lasarte JJ, Mansilla C, Esparza I, Irache JM, Gamazo C. 2011 Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators. Vaccine 29, 7130-7135. (doi:10.1016/j.vaccine.2011.05.072)
99. Moghimi SM, Hunter AC. 2000 Poloxamers and poloxamines in nanoparticles engineering and experimental medicine. Trends Biotechnol. 18, 412-420. (doi:10.1016/S0167-7799(00)01485-2)
100. Howerton DA, Hunter RL, Ziegler HK, Check IJ. 1990 Induction of macrophage Ia expression in vivo by synthetic copolymer L81. J. Immunol. 144, 1578-1584. (Pubitemid 20093983)
101. Robinson SN, Chavez JM, Pisarev VM, Mosley RL, Rosenthal GJ, Blonder JM, Talmadge JE. 2003 Delivery of Flt3 ligand (Flt3L) using a poloxamer-based formulation increases biological activity in mice. Bone Marrow Transplant. 31, 361-369. (doi:10.1038/sj.bmt.1703816)
102. Hunter RL, Bennett B. 1984 The adjuvant activity of non-ionic block polymer surfactants. II. Antibody formation and inflammation to the structure of triblocks and octablock copolymers. J. Immunol. 133, 3167-3175. (Pubitemid 15218266)
103. Hunter RL, Bennett B. 1986 The adjuvant activity of non-ionic block polymer surfactants. Ill. Characterization of selected biologically active surfaces. Scand. J. Immunol. 23, 287-300. (doi:10.1111/j.1365-3083.1986.tb01970. x)
104. Discher DE, Ahmed F. 2006 Polymerasomes. Annu. Rev. Biomed. Eng. 8, 323-341. (doi:10.1146/annurev.bioeng.8.061505.095838)
105. Holowka EP, Sun VZ, Kamei DT, Deming TJ. 2007 Polyarginine segments in block copolypeptides drive both vesicular assembly and intracellular delivery. Nat. Mater. 6, 52-57. (doi:10.1038/nmat1794)
106. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. 2006 In vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles. J. Control. Release 112, 26-34. (doi:10.1016/j.jconrel.2006.01. 006)
107. Rehor A, Hubbell JA, Tirelli N. 2005 Oxidation-sensitive polymeric nanoparticles. Langmuir 21, 411-417. (doi:10.1021/la0478043)
108. Stieneker F, Kersten G, van Bloois L, Crommelin DJ, Hem SL, Löwer J, Kreuter J. 1995 Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 13, 45-53. (doi:10.1016/0264-410X(95) 80010-B)
109. Kreuter J, Mauler R, Gruschkau H, Speiser PP. 1976 The use of new polymethylmethacrylate adjuvants for split influenza vaccines. Exp. Cell Biol. 44, 12-19.
110. Kreuter J, Liehl E. 1978 Protection induced by inactivated influenza virus vaccines with polymethylmethacrylate adjuvants. Med. Microbiol. Immunol. 165, 111-117. (doi:10.1007/BF02122746)
111. Ji W, Panus D, Palumbo RN, Tang R, Wang C. 2011 Poly(2-aminoethyl methacrylate) with well defined chain length for DNA vaccine delivery to dendritic cells. Biomacromolecules 12, 4373-4385. (doi:10.1021/bm201360v)
112. Hu Y, Litwin T, Nagaraja AR, Kwong B, Katz J, Watson N, Irvine DJ. 2007 Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett. 7, 3056-3064. (doi:10.1021/nl071542i)
113. Hu Y, Atukorale PU, Lu JJ, Moon JJ, Um SH, Cho EC, Wang Y, Chen J, Irvine DJ. 2009 Cytosolic delivery mediated via electrostatic surface binding of protein, virus, or siRNA cargos to pH-responsive core-shell gel particles. Biomacromolecules 10, 756-765. (doi:10.1021/bm801199z)
114. Beaudette TT et al. 2009 In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in aciddegradable microparticle vaccines. Mol. Pharmacol. 6, 1160-1169. (doi:10.1021/mp900038e)
115. Jong S et al. 2007 Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol. Immunother. 56, 1251-1264. (doi:10.1007/s00262-006-0276-x)
116. Prasad S, Cody V, Saucier-Sawyer JK, Saltzman WM, Sasaki CT, Edelson RL, Birchall MA, Hanlon DJ. 2011 Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine 7, 1-10.
117. Slutter B et al. 2010 Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice. against the encapsulated antigen. Vaccine 28, 6282-6291.
118. Brunner R, Jensen-Jarolim E, Pali-Scholl I. 2010 The ABC of clinical and experimental adjuvants: a brief overview. Immunol. Lett. 128, 29-35. (doi:10.1016/j.imlet.2009.10.005)
119. Diwan M, Elamanchili P, Cao M, Samuel J. 2004 Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr. Drug Delivery 1, 405-412. (doi:10.2174/1567201043334597)
120. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM, Hanlon DJ. 2006 Enhanced and prolonged crosspresentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117, 78-88. (doi:10.1111/j.1365-2567.2005.02268.x)
121. Kelly C, Jefferies C, Cryan SA. 2011 Targeted liposomal drug delivery to monocytes and macrophages. J. Drug Delivery 2011, 1-11. (doi:10.1155/2011/ 727241)
122. Jain RA. 2000 The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475-2490. (doi:10.1016/S0142-9612(00)00115-0)
123. Baras B, Benoit MA, Dupre L, Poulain-Godefroy O, Schacht AM, Capron A, Gillard J, Riveau G. 1999 Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen. Infect. Immun. 67, 2643-2648. (Pubitemid 29200533)
124. Mata E, Igartua M, Patarroyo ME, Pedraz JL, Hernández RM. 2011 Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. Eur. J. Pharm. Sci. 44, 32-40. (doi:10.1016/j.ejps.2011.05.015)
125. Martínez Gómez JM, Csaba N, Fischer S, Sichelstiel A, Kündig TM, Gander B, Johansen P. 2008 Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. J. Control. Release 130, 161-167. (doi:10.1016/j. jconrel.2008.06.003)
126. Mueller M, Schlosser E, Gander B, Groettrup M. 2011 Tumor eradication by immunotherapy with biodegradable PLGA microspheres - an alternative to incomplete Freund's adjuvant. Int. J. Cancer 129, 407-416. (doi:10.1002/ijc. 25914)
127. Temmerman MLD, Rejman J, Vandenbroucke RE, Koker SD, Libert C, Grooten J, Demeester J, Gander B, Smedt SCD. 2012 Polyelectrolyte LbL microcapsules versus PLGA microparticles for immunization with a protein antigen. J. Control. Release 158, 233-239. (doi:10.1016/j.jconrel.2011.10.029)
128. Singh J, Pandit S, Bramwell VW, Alpar HO. 2006 Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38, 96-105. (doi:10.1016/j.ymeth.2005.11.003)
129. Palumbo RN, Zhong X, Panus D, Han W, Ji W, Wang C. 2012 Transgene expression and local tissue distribution of naked and polymer-condensed plasmid DNA after intradermal administration in mice. J. Control. Release 159, 232-239. (doi:10.1016/j.jconrel.2012.01.012)
130. Makela O, Seppala IJ, Vaara M. 1983 LPS greatly enhances the antibody response to hapten-polysaccharide conjugates, but not to hapten-protein conjugates. Annu. Rev. Immunol. 134D, 25-36.
131. Ohno N et al. 1999 Solubilization of yeast cell-wall β-(1/3)-D- glucan by sodium hypochlorite oxidation and dimethyl sulfoxide extraction. Carbohydrate Res. 316, 161-172. (doi:10.1016/S0008-6215(99)00049-X)
132. Hida S, Miura NN, Adachi Y, Ohno N. 2007 Cell wall β-glucan derived from Candida albicans acts as a trigger for autoimmune arthritis in SKG mice. Biol. Pharm. Bull. 30, 1589-1592. (doi:10.1248/bpb.30.1589)
133. Keystone EC, Schorlemmer HU, Pope C, Allison AC. 1977 Zymosan-induced arthritis. Arthritis Rheum. 20, 1396-1401. (doi:10.1002/art.1780200714)
134. Kelkka T, Hultqvist M, Nandakumar KS, Holmdahl R. 2012 Enhancement of antibody-induced arthritis via toll-like receptor 2 stimulation is regulated by granulocyte reactive oxygen species. Am. J. Pathol. 181, 141-150. (doi:10.1016/j.ajpath.2012.03.031)
135. Hultqvist M, Nandakumar KS, Björklund U, Holmdahl R. 2010 Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Annal. Rheum. Dis. 69, 1527-1532. (doi:10.1136/ard.2009.121178)
136. Shenoy M, Christadoss P. 1983 Induction of experimental autoimmune myasthenia gravis with acetylcholine receptors using a non-ionic copolymer as adjuvant. Immunol. Invest. 22, 267-282. (doi:10.3109/08820139309063408)
137. Shakya AK, Kumar A, Nandakumar KS. 2011 Adjuvant properties of a biocompatible thermoresponsive polymer of N-isopropylacrylamide in autoimmunity and arthritis. J. R. Soc. Interface 8, 1748-1759. (doi:10.1098/rsif.2011.0114)
138. Shakya AK, Kumar A, Klaczkowska D, Hultqvist M, Hagenow K, Holmdahl R, Nandakumar KS. 2011 Collagen type II and a thermo-responsive polymer of N-isopropylacrylamide induce arthritis independent of Toll-like receptors: a strong influence by major histocompatibility complex class II and Ncf1 genes. Am. J. Pathol. 179, 2490-2500. (doi:10.1016/j.ajpath.2011.07.034)
139. Goldblum RM, Pelley RP, O'Donell AA, Pyron D, Heggers JP. 1992 Antibodies to silicone elastomers and reactions to ventriculoperitoneal shunts. Lancet 340, 510-513. (doi:10.1016/0140-6736(92)91710-P)
140. Bekerecioglu M, Onat AM, Tercan M, Buyukhatipoglu H, Karakok M, Isik D, Bulut O. 2008 The association between silicone implants and both antibodies and autoimmune diseases. Clin. Rheumatol. 27, 147-150. (doi:10.1007/s10067-007-0659- 1)
141. Louis JA, Lambert PH. 1979 Lipopolysaccharides: from immunostimulation to autoimmunity. Immunopathology 2, 215-228. (Pubitemid 10228842)
142. Hida S, Miura NN, Adachi Y, Ohno N. 2005 Effect of Candida albicans cell wall glucan as adjuvant for induction of autoimmune arthritis in mice. J. Autoimmunity 25, 93-101. (doi:10.1016/j.jaut.2005.06.002)
143. Hida S, Nagi-Miura N, Adachi Y, Ohno N. 2006 β-Glucan derived from zymosan acts as an adjuvant for collagen-induced arthritis. Microbiol. Immunol. 50, 453-461.
144. Claman HN. 1963 Tolerance to a protein antigen in adult mice and the effect of non-specific factors. J. Immunol. 91, 833-839.
145. Seppala IJ, Mxkelx O. 1984 Adjuvant effect of bacterial LPS and/or alum precipitation in responses to polysaccharide and protein antigens. Immunology 53, 827-836. (Pubitemid 15209940)
146. Liideritz O, Westphal O, Staub AM, Nikaido H. 1971 Isolation and chemical and immunological characterization of bacterial lipopolysaccharide. In vol. 4 (eds G Weinbaum, S Kadis, SJ Ajl), pp. 145. New York, NY: Academic Press.
147. Louis JA, Chiller JM, Weigle WO. 1973 The ability of bacterial lipopolysvccharide to modulate the induction of unresponsiveness to a state of immunity. Cellular parameters. J. Exp. Med. 138, 1481-1495. (doi:10.1084/jem. 138.6.1481)
148. Franzl RE, Mcmaster PD. 1968 The primary immune response in mice. I. The enhancement and suppression of hemolysin production by a bacterial endotoxin. J. Exp. Med. 127, 1087-1107. (doi:10.1084/jem.127.6.1087)
149. Adachi Y, Suzuki Y, Ohno N, Yadomae T. 1998 Adjuvant effect of grifolan on antibody production in mice. Biol. Pharm. Bull. 21, 974-977. (doi:10.1248/bpb.21.974)
150. Kurihara K, Shingo Y, Miura NN, Horie S, Usui Y, Adachi Y, Yadomae T, Ohno N. 2003 Effect of CAWS, a mannoprotein-beta-glucan complex of Candida albicans, on leukocyte, endothelial cell, and platelet functions in vitro. Biol. Pharm. Bull. 26, 233-240. (doi:10.1248/bpb.26.233)
151. Ohno N. 2003 Chemistry and biology of angiitis inducer, Candida albicans water-soluble mannoprotein-beta-glucan complex (CAWS). Microbiol. Immunol. 47, 479-490. (Pubitemid 36898676)
152. Tokunaka K, Ohno N, Adachi Y, Tanaka S, Tamura H, Yadomae T. 2000 Immunopharmacological and immunotoxicological activities of a watersoluble (1/3)-beta-D-glucan, CSBG from Candida spp. Int. J. Immunopharmacol. 22, 383-394. (doi:10.1016/S0192-0561(99)00093-4)
153. Sato M et al. 2003 Direct binding of Toll-like receptor 2 to zymosan, and zymosan induced NF-κB activation and TNF-α secretion are down-regulated by lung collectin surfactant protein A. J. Immunol. 171, 417-425. (Pubitemid 36745315)
154. Dillon S et al. 2006 Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest. 116, 916-928. (doi:10.1172/JCI27203)
155. Ibusuki S, Matsuda T, Iwamoto Y. 2003 Tissue engineered cartilage using thermo-responsive gelatin as an in situ forming and moldable scaffold with chondrocytes: in vitro and in vivo performances. Arthritis Res. Ther. 5, 61. (doi:10.1186/ar862)
156. Agmon-Levin N, Hughes GRV, Shoenfeld Y. 2012 The spectrum of ASIA: 'autoimmune (autoinflammatory) syndrome induced by adjuvants. Lupus 21, 118-120. (doi:10.1177/0961203311429316)
157. Schaefer CJ, Wooley PH. 1999 The influence of silicone implantation on murine lupus in MRL lpr/lpr mice. J. Rheumatol. 26, 2215-2221. (Pubitemid 29487020)
158. Zandman-Goddard G, Blank M, Ehrenfeld M, Gilburd B, Peter J, Shoenfeld Y. 1999 A comparison of autoantibody production in asymptomatic and symptomatic women with silicone breast implants. J. Rheumatol. 26, 73-77. (Pubitemid 29051398)
159. Nancy AL, Shoenfeld Y. 2008 Chronic fatigue syndrome with autoantibodies-the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun. Rev. 8, 52-55. (doi:10.1016/j.autrev.2008.07. 026)
160. Kumagai Y, Shiokawa Y, Medsger TAJ, Rodnan GP. 1984 Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum. 27, 1-12. (doi:10.1002/art.1780270101)
161. Chizzolini C. 2007 Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Annal. Med. 39, 42-53. (doi:10.1080/07853890601098152)